Menu Search Icon

Search

Department of Pathology

Charles Landen, M.D.

Charles Landen M.D.
Associate Professor of Obstetrics and Gynecology

Education

  • BS, University of North Carolina at Chapel Hill
  • MD, University of North Carolina at Chapel Hill
  • MS, University of Texas Health Sciences Center, Houston

Contact

  • Phone: 243-6131
  • Email: cl3nj

Research Interest(s)

Mechanisms of Chemotherapy Resistance in Ovarian and Other Gynecologic Malignancies

Research Description

Dr. Landen’s research focus is on novel therapeutics and chemotherapy resistance in gynecologic cancers, primarily ovarian cancer. He conducts preclinical and clinical research developing models to better-understand the pathways contributing to chemotherapy resistance and how recurrence develops. Mechanisms he has focused on include cancer stem cells, ABC transporters, and the Notch, Hedgehog, and Wnt pathways. His investigations have led to development of clinical trials seeking to overcome chemotherapy resistance. Clinically, his areas of interest include minimally invasive surgery, management of primary and recurrent ovarian cancer, and sentinel node dissections. He is the Associate Leader of the Women’s Oncology Program in the UVA Cancer Center.

Selected Publications

  • Arend R, Londoño-Joshi A, Samant R, Li Y, Conner M, Hidalgo B, Alvarez R, Landen C, Straughn J, Buchsbaum D. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecologic oncology. 2014;134(1): 112-20. PMID: 24736023
  • Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O’Connor M, Blumer J, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood A, Landen C, Eblen S. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014;35(5): 1100-9. PMID: 24379240 | PMCID: PMC4004201
  • Dobbin Z, Katre A, Steg A, Erickson B, Shah M, Alvarez R, Conner M, Schneider D, Chen D, Landen C. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget. 2014;5(18): 8750-64. PMID: 25209969
  • Dobbin Z, Landen C. Isolation and characterization of potential cancer stem cells from solid human tumors–potential applications. Current protocols in pharmacology / editorial board, S.J. Enna (editor-in-chief) … [et al.]. 2014;63 Unit 14.28.. PMID: 24510756 | PMCID: PMC4041697
  • Shah M, Dobbin Z, Nowsheen S, Wielgos M, Katre A, Alvarez R, Konstantinopoulos P, Yang E, Landen C. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecologic oncology. 2014;134(2): 331-7. PMID: 24844596
  • Steg A, Burke M, Amm H, Katre A, Dobbin Z, Jeong D, Landen C. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget. 2014;5(16): 7065-80. PMID: 25216523 | PMCID: PMC4196184
  • Chen H, Landen C, Li Y, Alvarez R, Tollefsbol T. Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane. Journal of oncology. 2013;2013 872957. PMID: 23476648 | PMCID: PMC3588178
  • Chen H, Landen C, Li Y, Alvarez R, Tollefsbol T. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Experimental cell research. 2013;319(5): 697-706. PMID: 23333498 | PMCID: PMC3577973
  • Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Frontiers in oncology. 2013;3 251. PMID: 24069583 | PMCID: PMC3781360
  • Dobbin Z, Landen C. The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer. International journal of molecular sciences. 2013;14(4): 8213-27. PMID: 23591839 | PMCID: PMC3645739
  • Erickson B, Conner M, Landen C. The role of the fallopian tube in the origin of ovarian cancer. American journal of obstetrics and gynecology. 2013;209(5): 409-14. PMID: 23583217 | PMCID: PMC3937451
  • Erickson B, Landen C, Conner M. Reply: To PMID 23583217. American journal of obstetrics and gynecology. 2013;209(4): 396. PMID: 23665249
  • Fauci J, Sabbatino F, Wang Y, Londoño-Joshi A, Straughn J, Landen C, Ferrone S, Buchsbaum D. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic oncology. 2013;132(1): 203-10. PMID: 24216048
  • Landen C, Lengyel E. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecologic oncology. 2013;130(1): 6-8. PMID: 23926600
  • Schultz M, Swindall A, Wright J, Sztul E, Landen C, Bellis S. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. Journal of ovarian research. 2013;6(1): 25. PMID: 23578204 | PMCID: PMC3637436
  • Shah M, Landen C. Ovarian cancer stem cells: are they real and why are they important? Gynecologic oncology. 2013;132(2): 483-9. PMID: 24321398
  • Kim K, Zsebik G, Straughn J, Landen C. Management of complex pelvic masses using a multivariate index assay: a decision analysis. Gynecologic oncology. 2012;126(3): 364-8. PMID: 22659191 | PMCID: PMC3696192
  • Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin Z, Li T, Hua X, Landen C, Birrer M, Sánchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Molecular cancer research : MCR. 2012;10(11): 1462-72. PMID: 22964433 | PMCID: PMC3501543
  • Qin Y, Xu J, Aysola K, Oprea G, Reddy A, Matthews R, Okoli J, Cantor A, Grizzle W, Partridge E, Reddy E, Landen C, Rao V. BRCA1 proteins regulate growth of ovarian cancer cells by tethering Ubc9. American journal of cancer research. 2012;2(5): 540-8. PMID: 22957306 | PMCID: PMC3433105
  • Steg A, Katre A, Bevis K, Ziebarth A, Dobbin Z, Shah M, Alvarez R, Landen C. Smoothened antagonists reverse taxane resistance in ovarian cancer. Molecular cancer therapeutics. 2012;11(7): 1587-97. PMID: 22553355 | PMCID: PMC3392529
  • Stone R, Nick A, McNeish I, Balkwill F, Han H, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena G, Pecot C, Coward J, Deavers M, Vasquez H, Urbauer D, Landen C, Hu W, Gershenson H, Matsuo K, Shahzad M, King E, Tekedereli I, Ozpolat B, Ahn E, Bond V, Wang R, Drew A, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf S, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood A. Paraneoplastic thrombocytosis in ovarian cancer. The New England journal of medicine. 2012;366(7): 610-8. PMID: 22335738 | PMCID: PMC3296780
  • Ziebarth A, Landen C, Alvarez R. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clinical obstetrics and gynecology. 2012;55(1): 156-72. PMID: 22343235
  • Ziebarth A, Nowsheen S, Steg A, Shah M, Katre A, Dobbin Z, Han H, Lopez-Berestein G, Sood A, Conner M, Yang E, Landen C. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;19(1): 170-82. PMID: 23147994 | PMCID: PMC3537868
  • Frederick P, Ramirez P, McQuinn L, Milam M, Weber D, Coleman R, Gershenson D, Landen C. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(5): 831-6. PMID: 21613957
  • Nick A, Stone R, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill W, Landen C, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim H, Lee J, Kim S, Baggerly K, Ram P, Deavers M, Coleman R, Lopez-Berestein G, Sood A. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. Journal of the National Cancer Institute. 2011;103(21): 1596-612. PMID: 21957230 | PMCID: PMC3206039
  • Steg A, Bevis K, Katre A, Ziebarth A, Dobbin Z, Alvarez R, Zhang K, Conner M, Landen C. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;18(3): 869-81. PMID: 22142828 | PMCID: PMC3271164
  • Steg A, Katre A, Goodman B, Han H, Nick A, Stone R, Coleman R, Alvarez R, Lopez-Berestein G, Sood A, Landen C. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(17): 5674-85. PMID: 21753153 | PMCID: PMC3166981
  • Landen C, Goodman B, Katre A, Steg A, Nick A, Stone R, Miller L, Mejia P, Jennings N, Gershenson D, Bast R, Coleman R, Lopez-Berestein G, Sood A. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Molecular cancer therapeutics. 2010;9(12): 3186-99. PMID: 20889728 | PMCID: PMC3005138
  • Merritt W, Kamat A, Hwang J, Bottsford-Miller J, Lu C, Lin Y, Coffey D, Spannuth W, Nugent E, Han L, Landen C, Nick A, Stone R, Coffman K, Bruckheimer E, Broaddus R, Gershenson D, Coleman R, Sood A. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer biology & therapy. 2010;10(12): 1306-14. PMID: 20948320 | PMCID: PMC3047089
  • Worley M, Landen C, Slomovitz B, Malpica A, Palla S, Ramirez P. Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2010;18(6): 509-11. PMID: 20661130
  • Kim T, Landen C, Lin Y, Mangala L, Lu C, Nick A, Stone R, Merritt W, Armaiz-Pena G, Jennings N, Coleman R, Tice D, Sood A. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer biology & therapy. 2009;8(23): 2263-72. PMID: 19829059 | PMCID: PMC3400500
  • Lee J, Han H, Shahzad M, Kim S, Mangala L, Nick A, Lu C, Langley R, Schmandt R, Kim H, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice D, Landen C, Coleman R, Sood A. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute. 2009;101(17): 1193-205. PMID: 19641174 | PMCID: PMC2736292
  • Lu C, Shahzad M, Moreno-Smith M, Lin Y, Jennings N, Allen J, Landen C, Mangala L, Armaiz-Pena G, Schmandt R, Nick A, Stone R, Jaffe R, Coleman R, Sood A. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer biology & therapy. 2009;9(3): 176-82. PMID: 20009575 | PMCID: PMC3155813
  • Shahzad M, Lu C, Lee J, Stone R, Mitra R, Mangala L, Lu Y, Baggerly K, Danes C, Nick A, Halder J, Kim H, Vivas-Mejia P, Landen C, Lopez-Berestein G, Coleman R, Sood A. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer biology & therapy. 2009;8(11): 1027-34. PMID: 19395869 | PMCID: PMC2748749
  • Cole M, Broaddus R, Thaker P, Landen C, Freedman R. Placental-site trophoblastic tumors: a case of resistant pulmonary metastasis. Nature clinical practice. Oncology. 2008;5(3): 171-5. PMID: 18227827
  • Han L, Fletcher M, Urbauer D, Mueller P, Landen C, Kamat A, Lin Y, Merritt W, Spannuth W, Deavers M, De Geest K, Gershenson D, Lutgendorf S, Ferrone S, Sood A. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(11): 3372-9. PMID: 18519766 | PMCID: PMC3426216
  • Landen C, Birrer M, Sood A. Early events in the pathogenesis of epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(6): 995-1005. PMID: 18195328
  • Landen C, Kim T, Lin Y, Merritt W, Kamat A, Han L, Spannuth W, Nick A, Jennnings N, Kinch M, Tice D, Sood A. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia (New York, N.Y.). 2008;10(11): 1259-67. PMID: 18953435 | PMCID: PMC2570602
  • Lin Y, Immaneni A, Merritt W, Mangala L, Kim S, Shahzad M, Tsang Y, Armaiz-Pena G, Lu C, Kamat A, Han L, Spannuth W, Nick A, Landen C, Wong K, Gray M, Coleman R, Bodurka D, Brinkley W, Sood A. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(17): 5437-46. PMID: 18765535 | PMCID: PMC2766914
  • Lu C, Shahzad M, Wang H, Landen C, Kim S, Allen J, Nick A, Jennings N, Kinch M, Bar-Eli M, Sood A. EphA2 overexpression promotes ovarian cancer growth. Cancer biology & therapy. 2008;7(7): 1098-103. PMID: 18443431 | PMCID: PMC2705979
  • Lu C, Thaker P, Lin Y, Spannuth W, Landen C, Merritt W, Jennings N, Langley R, Gershenson D, Yancopoulos G, Ellis L, Jaffe R, Coleman R, Sood A. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. American journal of obstetrics and gynecology. 2008;198(4): 477.e1-9; discussion 477.e9-10. PMID: 18395047 | PMCID: PMC2346589
  • Merritt W, Lin Y, Spannuth W, Fletcher M, Kamat A, Han L, Landen C, Jennings N, De Geest K, Langley R, Villares G, Sanguino A, Lutgendorf S, Lopez-Berestein G, Bar-Eli M, Sood A. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Journal of the National Cancer Institute. 2008;100(5): 359-72. PMID: 18314475 | PMCID: PMC2770251
  • Kamat A, Kim T, Landen C, Lu C, Han L, Lin Y, Merritt W, Thaker P, Gershenson D, Bischoff F, Heymach J, Jaffe R, Coleman R, Sood A. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer research. 2007;67(1): 281-8. PMID: 17210709
  • Kamat A, Merritt W, Coffey D, Lin Y, Patel P, Broaddus R, Nugent E, Han L, Landen C, Spannuth W, Lu C, Coleman R, Gershenson D, Sood A. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(24): 7487-95. PMID: 18094433
  • Kim T, Ravoori M, Landen C, Kamat A, Han L, Lu C, Lin Y, Merritt W, Jennings N, Spannuth W, Langley R, Gershenson D, Coleman R, Kundra V, Sood A. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer research. 2007;67(19): 9337-45. PMID: 17909042
  • Landen C, Lin Y, Armaiz Pena G, Das P, Arevalo J, Kamat A, Han L, Jennings N, Spannuth W, Thaker P, Lutgendorf S, Savary C, Sanguino A, Lopez-Berestein G, Cole S, Sood A. Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer research. 2007;67(21): 10389-96. PMID: 17974982
  • Landen C, Lin Y, Immaneni A, Deavers M, Merritt W, Spannuth W, Bodurka D, Gershenson D, Brinkley W, Sood A. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(14): 4098-104. PMID: 17634535
  • Lu C, Kamat A, Lin Y, Merritt W, Landen C, Kim T, Spannuth W, Arumugam T, Han L, Jennings N, Logsdon C, Jaffe R, Coleman R, Sood A. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(14): 4209-17. PMID: 17634550
  • Ramirez P, Landen C, Coleman R, Milam M, Levenback C, Johnston T, Gershenson D. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecologic oncology. 2007;108(1): 68-71. PMID: 17905421
  • Halder J, Kamat A, Landen C, Han L, Lutgendorf S, Lin Y, Merritt W, Jennings N, Chavez-Reyes A, Coleman R, Gershenson D, Schmandt R, Cole S, Lopez-Berestein G, Sood A. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(16): 4916-24. PMID: 16914580 | PMCID: PMC3144499
  • Han L, Landen C, Trevino J, Halder J, Lin Y, Kamat A, Kim T, Merritt W, Coleman R, Gershenson D, Shakespeare W, Wang Y, Sundaramoorth R, Metcalf C, Dalgarno D, Sawyer T, Gallick G, Sood A. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer research. 2006;66(17): 8633-9. PMID: 16951177 | PMCID: PMC3202609
  • Kamat A, Bischoff F, Dang D, Baldwin M, Han L, Lin Y, Merritt W, Landen C, Lu C, Gershenson D, Simpson J, Sood A. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer biology & therapy. 2006;5(10): 1369-74. PMID: 16969071
  • Kamat A, Fletcher M, Gruman L, Mueller P, Lopez A, Landen C, Han L, Gershenson D, Sood A. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(6): 1707-14. PMID: 16551853 | PMCID: PMC3202606
  • Landen C, Lu C, Han L, Coffman K, Bruckheimer E, Halder J, Mangala L, Merritt W, Lin Y, Gao C, Schmandt R, Kamat A, Li Y, Thaker P, Gershenson D, Parikh N, Gallick G, Kinch M, Sood A. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. Journal of the National Cancer Institute. 2006;98(21): 1558-70. PMID: 17077358
  • Landen C, Merritt W, Mangala L, Sanguino A, Bucana C, Lu C, Lin Y, Han L, Kamat A, Schmandt R, Coleman R, Gershenson D, Lopez-Berestein G, Sood A. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer biology & therapy. 2006;5(12): 1708-13. PMID: 17106249
  • Lin Y, Han L, Kamat A, Merritt W, Landen C, Deavers M, Fletcher M, Urbauer D, Kinch M, Sood A. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2006;109(2): 332-40. PMID: 17154180
  • Merritt W, Thaker P, Landen C, Deavers M, Fletcher M, Lin Y, Han L, Kamat A, Schmandt R, Gershenson D, Kinch M, Sood A. Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer biology & therapy. 2006;5(10): 1357-60. PMID: 16969087
  • Sood A, Bhatty R, Kamat A, Landen C, Han L, Thaker P, Li Y, Gershenson D, Lutgendorf S, Cole S. Stress hormone-mediated invasion of ovarian cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12(2): 369-75. PMID: 16428474 | PMCID: PMC3141061
  • Thaker P, Han L, Kamat A, Arevalo J, Takahashi R, Lu C, Jennings N, Armaiz-Pena G, Bankson J, Ravoori M, Merritt W, Lin Y, Mangala L, Kim T, Coleman R, Landen C, Li Y, Felix E, Sanguino A, Newman R, Lloyd M, Gershenson D, Kundra V, Lopez-Berestein G, Lutgendorf S, Cole S, Sood A. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature medicine. 2006;12(8): 939-44. PMID: 16862152
  • Halder J, Landen C, Lutgendorf S, Li Y, Jennings N, Fan D, Nelkin G, Schmandt R, Schaller M, Sood A. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(24): 8829-36. PMID: 16361572 | PMCID: PMC3144933
  • Han L, Landen C, Kamat A, Lopez A, Bender D, Mueller P, Schmandt R, Gershenson D, Sood A. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;24(5): 755-61. PMID: 16380413
  • Imai M, Landen C, Ohta R, Cheung N, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer research. 2005;65(22): 10562-8. PMID: 16288049
  • Landen C, Chavez-Reyes A, Bucana C, Schmandt R, Deavers M, Lopez-Berestein G, Sood A. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer research. 2005;65(15): 6910-8. PMID: 16061675
  • Landen C, Kinch M, Sood A. EphA2 as a target for ovarian cancer therapy. Expert opinion on therapeutic targets. 2005;9(6): 1179-87. PMID: 16300469
  • Landen C, Klingelhutz A, Coffin J, Sorosky J, Sood A. Genomic instability is associated with lack of telomerase activation in ovarian cancer. Cancer biology & therapy. 2004;3(12): 1250-3. PMID: 15477760
  • Thaker P, Deavers M, Celestino J, Thornton A, Fletcher M, Landen C, Kinch M, Kiener P, Sood A. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(15): 5145-50. PMID: 15297418
  • Landen C, Mathur S, Richardson M, Creasman W. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. American journal of obstetrics and gynecology. 2003;188(5): 1174-6. PMID: 12748469
  • Landen C, Younger N, Collins Sharp B, Underwood P. Cancer patients’ satisfaction with physicians: Princess Margaret Hospital Satisfaction with Doctor Questionnaire results. American journal of obstetrics and gynecology. 2003;188(5): 1177-9. PMID: 12748470
  • Mathur S, Landen C, Datta S, Hoffman M, Mathur R, Young R. Insulin-like growth factor II in gynecological cancers: a preliminary study. American journal of reproductive immunology (New York, N.Y. : 1989). 2003;49(2): 113-9. PMID: 12765350
  • Landen C, Zhang P, Young R. Differing mechanisms of inhibition of calcium increases in human uterine myocytes by indomethacin and nimesulide. American journal of obstetrics and gynecology. 2001;184(6): 1100-3. PMID: 11349169
  • Vermillion S, Landen C. Prostaglandin inhibitors as tocolytic agents. Seminars in perinatology. 2001;25(4): 256-62. PMID: 11561913
  • Liles D, Landen C, Monroe D, Lindley C, Read M, Roberts H, Brinkhous K. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thrombosis and haemostasis. 1997;77(5): 944-8. PMID: 9184407
  • Fang B, Eisensmith R, Wang H, Kay M, Cross R, Landen C, Gordon G, Bellinger D, Read M, Hu P. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Human gene therapy. 1995;6(8): 1039-44. PMID: 7578416
  • Kay M, Landen C, Rothenberg S, Taylor L, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson A. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(6): 2353-7. PMID: 8134398 | PMCID: PMC43369
  • Kay M, Rothenberg S, Landen C, Bellinger D, Leland F, Toman C, Finegold M, Thompson A, Read M, Brinkhous K. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science (New York, N.Y.). 1993;262(5130): 117-9. PMID: 8211118

 

In This Section down-arrow
Menu